Redhill Biopharma
RDHL
16 hedge funds and large institutions have $386K invested in Redhill Biopharma in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
4.86% less ownership
Funds ownership: 15% → 10.14% (-4.9%)
6% less funds holding
Funds holding: 17 → 16 (-1)
25% less capital invested
Capital invested by funds: $514K → $386K (-$128K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$16K |
| 2 |
SG
StoneX Group
New York
|
+$15.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$13.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.48K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$2.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
-$37.6K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$312 |
| 3 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
-$39 |
| 4 |
GAFA
Garton & Associates Financial Advisors
Louisville,
Kentucky
|
-$15 |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$4 |
RDHL Hedge Fund Activity: Q1 2026 in Review
16 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q1 2026, worth a combined $386K — down 25% from $514K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of RDHL and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was XTX Topco, opening a new position worth an estimated $16K. The largest seller was Yorkville Advisors Global, cutting an estimated $37.6K.
- 16 institutional investors held Redhill Biopharma (RDHL) as of Q1 2026, down from 17 in Q4 2025.
- Funds reported $386K of Redhill Biopharma stock for Q1 2026, down 25% quarter-over-quarter.
- 3 funds opened new Redhill Biopharma positions in Q1 2026 and 4 closed out, a net change of -1 holder.
- The largest Redhill Biopharma buyer in Q1 2026 was XTX Topco, an estimated $16K added.
- The largest Redhill Biopharma seller in Q1 2026 was Yorkville Advisors Global, an estimated $37.6K sold.
Based on aggregated 13F filings for Q1 2026.